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We report the molecular cloning of a p3-adrenergic receptor [B3-AR] cDNA from human brown adipose &sue. The cDNA-encoded protein IS 
identical to the previously clonedB3-AR but with 6 addttional amino acids at the C-termmus. The C-termmus 1s shared by the/33 receptors expressed 
m human neuroblastoma cells [SK-N-MC] [Mol. Pharmacol 42 (1992) 964-9701. Furthermore, using a polymerase cham reaction strategy we have 
cloned and sequenced the B3-AR introns Sequence analysts demonstrates that the human /33-AR gene comprises at least 3 exons and 2 introns 
and that the most abundant /?3-AR transcripts encode a protein with an exon 3-derived C-terminus. Interestmgly, although a similar organization 
has been found m rodent genes, the ratj33-AR transcripts encode a receptor wtth an exon 2-derived C-terminus. 
Intron; Alternative splicmg; Polymerase chain reactton 
1. INTRODUCTION 
The existence of atypical p-adrenergic receptors @- 
ARs) was postulated to explain the non-p1 - and non-B2- 
adrenergic responses of rat brown and white adipose 
tissues [l]. Since then, /?-ARs, pharmacologically simi- 
lar to those of adipocytes, have been found in colon 
[2,3], ileum [4], gastric fundus [5], heart [6] and skeletal 
muscle [7] of rodents. Subsequently, the molecular clon- 
ing of a gene related to the j?l- and P2-AR genes termed 
/?3, in human [S] and rodent [9912], has confirmed the 
existence of another B-AR with a similar tissue distribu- 
tion to that of the atypical P-ARs. Nevertheless, the 
pharmacological characteristics of the cloned rat or 
human P3-AR genes expressed by transfected CHO 
cells have raised a question concerning the relationship 
between atypical p- and P3-ARs [13]. Elements of ans- 
wer to that question were brought since the rodent and 
human P3-AR genes have been shown to contain in- 
tron(s) [12,14]. The splicing of intron(s) results in rodent 
as in SK-N-MC, a human neuroblastoma cell line, in 
the expression of a /?3-AR with several more amino 
acids at the C-terminus than receptors encoded by 
unspliced transcripts [14]. Interestingly, based on phar- 
macological evidence, the SK-N-MC p3-AR more 
closely resembles that of the cloned rat/33-AR than that 
of the cloned human P3-AR expressed from an unspli- 
ted version of the gene [15]. Therefore, the pharmacol- 
ogical discrepancies with the rat P-AR reported for the 
cloned human /33-AR might be related to its truncated 
C-terminus. To address the question of the primary 
structure of the human /?3-AR expressed in normal 
human tissues we have cloned the /?3-AR cDNA from 
human brown adipose tissue. Furthermore, using our 
cDNA sequence, we have determined the primary struc- 
ture of the human P3-AR introns. 
2. MATERIALS AND METHODS 
2 1. Construction und screemng of (I cDNA 1ibrurJ 
Total RNA from infant brown adipose ttssue was prepared by using 
the acid guamdmium isothiocyanate phenol chloroform method 1161. 
Poly(A)RNA was isolated from total RNA by oligo(dT)-cellulose 
chromatography as described by Aviv and Leder [17]. The cDNA 
library was constructed m the vector pTZl8 from Pharmacia using the 
primer-adapter procedure [18]. 2 x lo6 primary recombinants were 
analyzed as described by Grunstein and Hogness [ 191 using a labeled 
probe dertved from genomtc sequences. DNA sequences were deter- 
mined by the method of Sanger [20]. 
2.2. Polvmerase chum reuctlon / PCR i 
Speck primers derived from the cDNA sequence (posittons 1,299- 
1.320 and 1,741~1.717) were used to amphfy human genomic DNA 
as descrtbed by Bensatd 1121. The PCR product was blunt-ended. 
digested by SstI and inserted between the SfnaI and the Sstl sites of 
the Ml3 mp19 phage for cloning and sequencing. 
3. RESULTS 
Correspondence address D. Caput. Umte Biologie Moleculaire du 
Gene, Sanofi Elf Btorecherches, BP 137,31676 Labege Cedex, France. 
Fax: (33) (61) 39 86 37. 
Ten /?3-AR cDNAs were isolated from a human 
brown adipose tissue cDNA library. Fig. 1 shows the 
sequence of one of the p3-AR cDNAs obtained which 
represents the complete sequence of the 83 transcript. 
The longest open reading frame found encodes a pro- 
tein of 419 residues. The putative protein shows the 
classical structural features of G protein-coupled recep- 
tors and a complete identity with the p3-AR previously 
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AGCTAGAGAAGATGGCCCAGGCTGGGGAAGTCGCTCGCTCTCAT~CTTGCTGTCCCCTCCCCT 
GAGCCAGGTGATTTGGGAGACCCCCTCCTTCCTTCTTTCCCTACCGCCCCACGC~GACC 
CGGGGATGGCTCCGTGGCCTCACGAGAACAGCTCTCTTGCTCTCTT~CCCATG~CGGACCTCCCCA 
MAPWPHENSSLAPWPDLPT 
CCCTGGCGCCCAATACCGCCAACACCACCAGTGGGCTGCCAGG~TTCCGTffiGA~CGGCCC 
LAPNTANTSGLPGVPWEAAL 
TAGCCGGGGCCCTGCTGGCGCTGGCGGTGCTGGCCACCGTGGGAGGC~CCT~TGGTCA 
AGALLALAVLATVGGNLLVI 
TCGTGGCCATCGCCTGGACTCCGAGACTCCAGACCATGACC~CGTGTTCGTGACTTCGC 
v A I AWTPRLQTMTNVFVTSL 
TGGCCGCAGCCGACCTGGTGATGGGACTCCTGGTGGTGCCGCCGGCGGCCACCTTGGC~ 
AAADLVMGLLVVPPAATLAL 
TGACTGGCCACTGGCCGTTGGGCGCCACTGGCTGCGAGCTGTGGACCTCGGTGGACGTGC 
TGHWPLGATGCELWTSVDVL 
TGTGTGTGACCGCCAGCATCGRAACCCCTGTGCGCCCTG~CGTGGACCGCTACCTG~TG 
C V T A S IETLCALAVDRYLAV 
TGACCAACCCGCTGCGTTACGGCGCACTffiTCAAGCG 
TNPLRYGALVTKRCARTAV" 
TCCTGGTGTGGGTCGTGTCGGCCGCGGTGTCGTTTGCGCCCATCATGA~CAGT~TG~ 
LVWVVSAAVSFAP IMSQWWR 
GCGTAGGGGCCGACGCCGAGGCGCAGCGCTGCCACTCCRACCCGCGCTGCTGTGCCTTCG 
VGADAEAQRCHSNPRCCAFA 
CCTCCAACATGCCCTACGTGCTGCTGTCCTCCTCCGTCTCCTTCTACCTTCCTCTTCTCG 
SNMPYVLLSSSVSFYLPLL" 
TGATGCTCTTCGTCTACGCGCGGGTTTTCGTGGTGGCTACGCGCCAGCTGCGCTTGCTGC 
MLFVYARVFVVATRQLRLLR 
GCGGGGAGCTGGGCCGCTTTCCGCCCGAGGAGTCTCCGCCGGCGCCGTCGCGCTCTCTGG 
GELGRFPPEESPPAPSRSLA 
CCCCGGCCCCGGTGGGGACGTGCGCTCCGCCCGAAGGGGTCCGGCGGC 
PAPVGTCAPPEGVPACGRRP 
CCGCGCGCCTCCTGCCTCTCCGGGAACACCGGGCCCTGTGCACCTTGGGTCTCATCATGG 
ARLLPLREHRALCTLGLIMG 
GCACCTTCACTCTCTGCTGGTTGCCCTTCTTTCTGGCCAACGTGCTCCTGGGGG 
TFTLCWLPFFLANVLRALGG 
GCCCCTCTCTAGTCCCGGGCCCGGCTTTCCTTGCCCTGAATT 
PSLVPGPAFLALNWLGYANS 
CTGCCTTCAACCCGCTCATCTACTGCCGCAGCCCGGACTTTCGCAGCGCCTTCCGCCGTC 
AFNPLIYCRSPDFRSAFRRL 
TTCTGTGCCGCTGCGGCCGTCGCCTGCCTCCGGAGCCCTGCGCCGCCGCCCGCCCGGCCC 
LCRCGRRLPPEPCAAARPAL 
TCTTCCCCTCGGGCGTTCCTGCGGCCCGGAGCAGCCCAGCGCAGCCCAGGCTTT~C~C 
FPSGVPAARSSPAQPRLCQR 
GGCTCGACGGGGCTTCTTGGGGAGTTTCTTAGGCCTGAAGGCCTG~GGAC~G~GC~C~CTCTG 
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Fig. 1. Nucleotide and predicted amino acid sequences of the human /I3-AR cDNA. Polyadenylatlon sites are underhned. The bold amino acids 
indicate the addItIona residues compared to the previously published receptor. 
deduced from genomic DNA sequences [8], but with 6 
additional amino acids at the C-terminus. Sequence 
analysis of the 3’ untranslated region of the P3-AR 
cDNA identified 2 polyadenylation sites. Comparison 
of the ten isolated /?3-AR cDNAs demonstrated that the 
two polyadenylation sites are used to the same extent 
(see Fig. 1). Furthermore, a screening of the cDNA 
library using a common p probe identified only one 
/31-AR and no /I?-AR cDNAs out of 2 x lo6 primary 
recombinants, indicating a preponderance of ,83- over 
Bl-AR transcripts. 
An alignment of genomic and cDNA sequences 
shows a divergence after the position 1,332 of the 
cDNA. In order to determine the structure of the spliced 
DNA fragment, we performed a polymerase chain reac- 
tion (PCR) experiment on genomic DNA using as prim- 
ers a pair of oligonucleotides matching the positions 
1,299-1,320 and 1,741-1,717 of the cDNA sequence. A 
comparison between the amplified DNA and cDNA 
sequences revealed a 1,025 bp intron (Fig. 2a, positions 
3331,057). Its splicing from primary transcripts makes 
the exons 1 and 3 contiguous in /33 mRNAs (Fig. 2b). 
A search for potential splice junctions and open reading 
frame(s) within the intron revealed a potential exon at 
the positions 796859. Interestingly, this exon encodes 
12 amino acids which share 50% homology with rat and 
mouse/33-AR protein C-termini. Therefore, as recently 
reported for the rodent P3-AR genes [ 141, we postulated 
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Fig 2. Structure of the human B3-AR gene. (a) Nucleotide and ammo acid sequences of exon/mtron junctions of the human /?3-AR gene beginning 
with Ala39’. Bold characters indtcate donor splice sites. lntron sequences are m itahc. Underhned residues represent the carboxyl-terminal tall of 
the cDNA. (b) Schematic representation of the human /33-AR gene, with mature mRNA as blocks and the coding sequence filed. E, exon. 
that the human gene contains 3 exons and 2 introns 
(Fig. 2b) and as represented on the scheme of Fig. 2b, 
an alternative splicing can generate receptor isoforms 
with, respectively, 12 and 6 additional amino acids at 
their C-terminus with respect to the deduced protein 
from the unspliced RNA sequence. 
4. DISCUSSION 
We report here the molecular cloning of a human 
brown adipose tissue B3-AR cDNA and the discovery 
of introns within the gene. At the genomic level, the 
coding sequence of the P3-AR cDNA is interrupted by 
a DNA fragment of 1,025 bp. This intron starts with an 
in-frame stop codon with the result that unspliced tran- 
scripts will encode a C-terminal truncated protein. 
The previously reported human /33-AR was deduced 
from genomic DNA sequences [8] and is therefore 6 
amino acids shorter than the sequence derived from the 
cDNA. This C-terminal-truncated human /?3-AR ex- 
pressed in CHO cells shares with the cloned rat p3 re- 
ceptor a low affinity for naturally occurring catechol- 
amines but differs regarding the potencies and efficacies 
of noncatecholamine ‘atypical’ agonists and ‘typical’ 
antagonists [13]. A recent finding indicates that these 
differences are related to the ‘missing’ carboxyl-termi- 
nal tail of the CHO-expressed human P3-AR. Since, the 
/33-AR expressed in the human neuroblastoma cell line 
SK-N-MC which has the same C-terminus as the 
cDNA-encoded receptor [14], more closely resembles 
the cloned rat P3-AR than the CHO-expressed trun- 
cated human P3-AR [15]. To directly demonstrate this 
point, we have stably transfected CHO cells with the 
human p3-AR cDNA and are presently investigating 
the pharmacological characteristics of the CHO-ex- 
pressed full-length human j?3-AR. The C-terminus of 
the P2-AR has been shown to be involved with the 
desensitization process through the phosphorylation of 
specific sites by the B-AR kinase [21,22]. In rat, the 
/33-AR fails to undergo functional desensitization dur- 
ing short-term exposure [23] or down-regulation of re- 
ceptor expression during long-term exposure [24] to iso- 
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properenol, a non-specific agonist. Moreover, recent 
work reported different coupling properties with G pro- 
teins of two isoforms of the prostaglandin E receptor 
with different carboxyl-terminal domains and demon- 
strated the implication of the C-terminus in signaling 
from both a G protein to a receptor and from a receptor 
to a G protein [25]. In rodent as in man, alternative 
splicing of p3 primary transcripts can generate at least 
three isoforms of receptors with different C-termini 
(Fig. 2b). The polymerase chain reaction was used to 
determine the existence and the tissue distribution of /?3 
splice variants. Our results support the idea that alter- 
native splicing might take place in some tissues (manu- 
script in preparation). It is therefore of importance to 
evaluate the pharmacological differences between these 
b3-AR isoforms and especially receptor desensitization 
and the down-regulation of receptor expression. 
Acknorcle~lgm~ents. We thank Dr. N. Vita for sttmulating discussions 
and Dr. D. Shtre for Its crittcal readmg of the manuscript. 
REFERENCES 
111 
PI 
[31 
[41 
[51 
Fl 
171 
Arch. J.R.S.. Amsworth, A.T.. Cawthorne. M.A , Ptercy. V, 
Sennitt, M.V., Thody, V.. Wtlson. C. and Wtlson, S. (1984) Na- 
ture 309. 1633165. 
Bianchetti, A. and Manara. L. (1990) Br. J Pharmacol. 100. 
831-839. 
McLaughhn. D.P. and McDonald. A. (1990) Br. J. Pharmacol. 
101. 569-574 
Bond, R. and Clark. D. (1988) Br. J Pharmacol 95. 7733733 
Coleman, R.A.. Denyer, L.H. and Sheldrtck, K.E. ( 1987) Br. J. 
Pharmacol. Proc. Suppl. 90. 40P. 
Kaumann, A.J (1989) Trends Pharmacol. Sci. IO. 316-320. 
Chalhs, R.. Leighton, B., Wilson, S., Thurlby. P. and Arch, J. 
(1988) Btochem. Pharmacol 37. 947-950. 
[8] Emorine. L.J., Marullo. S.. Brtend-Suttren. M.M., Patey, G , 
Tate, K.. Delavter-Klutchko, C. and Strosberg. A.D. (1989) Sci- 
ence 245, 1118-1121. 
[9] Muzzm, P.. Revelli, J.P, Kuhne. F.. Gocayne. J., McCombie. R.. 
Venter, J.. Giacobino. J.P. and Fraser, C. (1991) J. Biol. Chem. 
266, 24053-24058. 
[lo] Granneman, J.G., Lahners, K.N and Chaudhry. A. (1991) Mol. 
Pharmacol. 40. 8955899. 
[I l] Nahmtas. C.. Bhn. N.. Elalouf. J . Mattel, M.G.. Strosberg. A.D 
and Emorme. L.J. (1991) EMBO J. 10. 3721-3727. 
[I21 Bensaid, M.. Kaghad. M., Rodrtguez. M.. Le Fur. G. and Caput, 
D. (1993) FEBS Lett 3. 2233226 
[13] Liggett. B. (1992) Mol. Pharmacol. 42. 634637. 
[14] Granneman, J G . Lahners. K.N. and Rao, D.D (1992) Mol. 
Pharmacol. 42, 964970. 
[15] Esbenshade, T.A., Han, C., Theroux. T.L.. Granneman, J.G. and 
Mmneman, K.P (1992) Mol. Pharmacol 42. 753-758. 
[16] Chomczynski, P. and Saccht. N. (1987) Anal. Biochem. 162. 156- 
159. 
[17] AVIV, H. and Leder. P. (1973) Proc. Nat1 Acad. Sci. USA 69. 
1408-1411. 
[IS] Caput, D.. Beutler, B.. Hartog. K.. Tayer. R., Brown-Schimer, 
S. and Cerami. A. (1986) Proc. Natl. Acad. Sci USA 83. 1670- 
1674. 
[19] Grunstein, M. and Hogness, D.S. (1975) Proc. Nat1 Acad. Set. 
USA 72. 3961-3964. 
[20] Sanger, F., Ntcklen. S. and Coulson. A.R. (1977) Proc. Natl. 
Acad SCI. USA 74. 5463 ~5467. 
[?I] Dohlman, H.G., Bouvier. M., Benovic, J.L.. Caron, M.G. and 
Lefkowttz, R J. (1987) J. Btol. Chem. 262, 14282-13288. 
[22] Bouvter. M.. Hausdorff. W.P. DeBlast. A.. O‘Down. B.F.. 
Kobtlka. B.K.. Caron. M.G. and Letkowttz, R.J. (1988) Nature 
333. 370~ 373. 
[23] Liggett. S., Schtwnn. D.A. and Lefkowttz, R.J. (1992) Clin. Res 
40. 252A. 
[24] Thomas. R.F.. Holt. B D.. Schiwn, D.A. and Ltggett, S. (1992) 
Proc Natl. Acad SCI. USA 89. 44904494. 
[25] Sugimoto. Y., Negtsht. M., Hayasht, Y., Namba, T.. Honda. A., 
Wdtabe. A.. Htrata, M.. Narumtya, S. and Ichtkawa. A. (1993) 
J. Btol. Chem. 268, 2712-2718 
130 
